Thu, Jul 10, 2014, 2:42 PM EDT - U.S. Markets close in 1 hr 18 mins

Recent

% | $
Quotes you view appear here for quick access.

Provectus Biopharmaceuticals, Inc. Message Board

  • diodia2000 diodia2000 Jan 23, 2014 7:08 PM Flag

    AF's "Obsolescence" of PV-10 is nonsense

    Feuerstein has one good argument in his article, that PVCT had said it was ready to go ahead with its phase 3 trial in November 2010 and had said that the FDA was on board. Then more than 3 years passed without any more formal trials.

    I believe PVCT was waiting for protection through patents, and that getting its October 2013 patent was the trigger to move toward approval. But I can't prove AF's explanation (that PVCT was afraid to do more trials) is wrong.

    But I feel certain that the FDA will not refuse to approve a phase 3 trial for PV-10 because it thinks other unapproved drugs, drugs with only phase 2 trial data (!) might turn out to be better, as AF claims:
    "Given the huge advances in melanoma care today, FDA might be telling Provectus that it cannot proceed with the phase III study, as planned." This is ridiculous. The criteria are safety and efficacy, not comparison with other unapproved drugs, such as Nivolumab and Lamprolizumab.

    In addition, his comparison of PV-10 with Allovectin's much, much weaker data is ridiculous as vandycommodores has shown.

    I also think is nonsense for AF to say that PVCT will not be able to find patients because all the patients out there are already signed up.

    The rest of the article is just name calling.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • it could be cost of a ph3. What would be the cost of a ph3?

      They will sell company. If BTD, at much higher price, if not, at a lower price. PFE has two on their advisory board.

    • Additionaly, his idea that their Phase 3 trial probably can't be conducted, because patients will be seeking the plethora of other melanoma drugs, is pure guesswork. One drug he cited, Bristol-Myers-Squibb's Yervoy, costs $120,000 in total for the treatment. While on the topic of Yeervoy, Feuerstein had no problem attacking Provectus's lead investigator of the Phase 2 Trials for PV-10. However, that same person was a co-investigator for the Yervoy trial.

      • 2 Replies to vandycommodores.1957
      • Oh Vandy so positive... LOL

      • Thursday, January 23, 2014
        I have really learned from and appreciated your posts, especially the ones on competitor drugs. I had a lot of the information on Yervoy and nivolumab and lambrolizumab from my due diligence, but you had a lot more! The info on Agarwala as an investigator for Yervoy was very welcome. AF must know this. I think his whole article was written in bad faith as was his Monday tweeting, as the blog CTD hints. Your calling his idea that no patients would be available for PVCT trials "guesswork" seems kind to me. I would call it "far-fetched." But we will find out before too long. Thanks for all the good info. Diodia

    • I am not sure about the patents... did they get the patents then? you think that might explain a more than 3 year delay? not sure, but it's really a long time for being so inactive. I wonder if the management really was paying itself the huge salaries all this time...

      • 1 Reply to fishfilter7
      • What I was saying is that the 3 years of inaction was Feuerstein's one good argument. I specifically said I could not be sure that the problem was the patents. I am not a biochemist. But look at how the trading of PVCT changed after October 24, 2013. It is suggestive. Why would PVCT spend $20 to $50 million to prove a drug works just so that any other firm could profit from selling it? Even Feuerstein alludes obliquely to the patent problem for PVCT of using a 130 year old off-patent drug (Rose Bengal).

        My point is that the "obselescence" argument is nonsense (and AF knows it), the "no patients available for PVCT" argument is ridiculous, and the comparison with Allovectin has no basis at all. All the rest of the article is just "OTC", "speculative," and other insults. Diodia

 
PVCT
1.04+0.010(+0.97%)2:34 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.